Biomarkers, laboratory, and animal models for the design and development of adjunctive therapies for HIV-1 dementia and other neuroinflammatory disorders

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

The goals of this component were to discuss the potential for NeuroAIDS therapeutics. The presentations included discussions of biomarkers, pathogenic mechanisms of disease, laboratory models, and the development of adjunctive therapies for neuroinflammatory and neurodegenerative disorders with a focus on NeuroAIDS. Talks by Dana Giulian on the use of CSF biomarkers for therapeutic trial design in dementia, Howard Fox on the SIV model of NeuroAIDS, Christine Zink on minocycline and its antiretroviral activities, and Katrina L. Mealey on the means to improve drug access to the brain by regulation P-glycoprotein, rounded out the session. It was acknowledged that although a number of compounds including selegiline, nimodipine, and memantine were studied in clinical trials and showed some trends towards clinical improvement none showed significance. Drugs such as minocycline, sodium valproate, and P-glycoprotein regulators were discussed and now are being developed. Partnerships between public institutions and private companies were discussed. Multidisciplinary teams are likely required to see such research to fruition, and the developmental schemes from the molecule to the laboratory to the animal to the clinic were discussed and developed in the session.

Original languageEnglish (US)
Pages (from-to)8-13
Number of pages6
JournalJournal of Neuroimmune Pharmacology
Volume2
Issue number1
DOIs
StatePublished - Mar 1 2007

Fingerprint

AIDS Dementia Complex
HIV-1
Minocycline
Animal Models
Biomarkers
P-Glycoprotein
Memantine
Selegiline
Nimodipine
Laboratory Animals
Valproic Acid
Neurodegenerative Diseases
Pharmaceutical Preparations
Dementia
Therapeutics
Clinical Trials
Brain
Research

Keywords

  • Anti-inflammatory
  • Blood-brain barrier
  • Microglia
  • P-glycoprotein
  • Preclinical therapeutics

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

@article{c9bad42bd8b4461da52dfe17af0e0ebe,
title = "Biomarkers, laboratory, and animal models for the design and development of adjunctive therapies for HIV-1 dementia and other neuroinflammatory disorders",
abstract = "The goals of this component were to discuss the potential for NeuroAIDS therapeutics. The presentations included discussions of biomarkers, pathogenic mechanisms of disease, laboratory models, and the development of adjunctive therapies for neuroinflammatory and neurodegenerative disorders with a focus on NeuroAIDS. Talks by Dana Giulian on the use of CSF biomarkers for therapeutic trial design in dementia, Howard Fox on the SIV model of NeuroAIDS, Christine Zink on minocycline and its antiretroviral activities, and Katrina L. Mealey on the means to improve drug access to the brain by regulation P-glycoprotein, rounded out the session. It was acknowledged that although a number of compounds including selegiline, nimodipine, and memantine were studied in clinical trials and showed some trends towards clinical improvement none showed significance. Drugs such as minocycline, sodium valproate, and P-glycoprotein regulators were discussed and now are being developed. Partnerships between public institutions and private companies were discussed. Multidisciplinary teams are likely required to see such research to fruition, and the developmental schemes from the molecule to the laboratory to the animal to the clinic were discussed and developed in the session.",
keywords = "Anti-inflammatory, Blood-brain barrier, Microglia, P-glycoprotein, Preclinical therapeutics",
author = "Gendelman, {Howard Eliot}",
year = "2007",
month = "3",
day = "1",
doi = "10.1007/s11481-006-9050-2",
language = "English (US)",
volume = "2",
pages = "8--13",
journal = "Journal of NeuroImmune Pharmacology",
issn = "1557-1890",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Biomarkers, laboratory, and animal models for the design and development of adjunctive therapies for HIV-1 dementia and other neuroinflammatory disorders

AU - Gendelman, Howard Eliot

PY - 2007/3/1

Y1 - 2007/3/1

N2 - The goals of this component were to discuss the potential for NeuroAIDS therapeutics. The presentations included discussions of biomarkers, pathogenic mechanisms of disease, laboratory models, and the development of adjunctive therapies for neuroinflammatory and neurodegenerative disorders with a focus on NeuroAIDS. Talks by Dana Giulian on the use of CSF biomarkers for therapeutic trial design in dementia, Howard Fox on the SIV model of NeuroAIDS, Christine Zink on minocycline and its antiretroviral activities, and Katrina L. Mealey on the means to improve drug access to the brain by regulation P-glycoprotein, rounded out the session. It was acknowledged that although a number of compounds including selegiline, nimodipine, and memantine were studied in clinical trials and showed some trends towards clinical improvement none showed significance. Drugs such as minocycline, sodium valproate, and P-glycoprotein regulators were discussed and now are being developed. Partnerships between public institutions and private companies were discussed. Multidisciplinary teams are likely required to see such research to fruition, and the developmental schemes from the molecule to the laboratory to the animal to the clinic were discussed and developed in the session.

AB - The goals of this component were to discuss the potential for NeuroAIDS therapeutics. The presentations included discussions of biomarkers, pathogenic mechanisms of disease, laboratory models, and the development of adjunctive therapies for neuroinflammatory and neurodegenerative disorders with a focus on NeuroAIDS. Talks by Dana Giulian on the use of CSF biomarkers for therapeutic trial design in dementia, Howard Fox on the SIV model of NeuroAIDS, Christine Zink on minocycline and its antiretroviral activities, and Katrina L. Mealey on the means to improve drug access to the brain by regulation P-glycoprotein, rounded out the session. It was acknowledged that although a number of compounds including selegiline, nimodipine, and memantine were studied in clinical trials and showed some trends towards clinical improvement none showed significance. Drugs such as minocycline, sodium valproate, and P-glycoprotein regulators were discussed and now are being developed. Partnerships between public institutions and private companies were discussed. Multidisciplinary teams are likely required to see such research to fruition, and the developmental schemes from the molecule to the laboratory to the animal to the clinic were discussed and developed in the session.

KW - Anti-inflammatory

KW - Blood-brain barrier

KW - Microglia

KW - P-glycoprotein

KW - Preclinical therapeutics

UR - http://www.scopus.com/inward/record.url?scp=33846813904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846813904&partnerID=8YFLogxK

U2 - 10.1007/s11481-006-9050-2

DO - 10.1007/s11481-006-9050-2

M3 - Review article

C2 - 18040820

AN - SCOPUS:33846813904

VL - 2

SP - 8

EP - 13

JO - Journal of NeuroImmune Pharmacology

JF - Journal of NeuroImmune Pharmacology

SN - 1557-1890

IS - 1

ER -